CLEC7A: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of CLEC7A. The page also collects GeneMedi's different modalities and formats products for CLEC7A in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CLEC7A target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

This gene encodes a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. The encoded glycoprotein is a small type II membrane receptor with an extracellular C-type lectin-like domain fold and a cytoplasmic domain with an immunoreceptor tyrosine-based activation motif. It functions as a pattern-recognition receptor that recognizes a variety of beta-1,3-linked and beta-1,6-linked glucans from fungi and plants, and in this way plays a role in innate immune response. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. This gene is closely linked to other CTL/CTLD superfamily members on chromosome 12p13 in the natural killer gene complex region. [provided by RefSeq, Jul 2008]

Pre-made anti-CLEC7A inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-CLEC7A benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CLEC7A mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Multi-species CLC7A/ CLEC7A/ BGR VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CLEC7A VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.

Pre-made CLEC7A viral vector in GM Promise-ORF^TM

About Promise-ORF^TM:
Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise-ORF^TM. Our collection of ORFs expression clones come in verified mammalian or viral vectors lentivirus, AAV, and adenovirus) and our Promise-ORF^TM viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection. Click to search your GOI

If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.